Cargando…

Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)

BACKGROUND: Chronic obstructive pulmonary disease (COPD) management in China is inadequate and there is a need to improve care and outcomes for patients nationwide. OBJECTIVES: The REAL study was designed to generate reliable information on COPD management from a representative sample of Chinese pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ting, Cai, Baiqiang, Cao, Bin, Kang, Jian, Wen, Fuqiang, Chen, Yahong, Jian, Wenhua, Wang, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126609/
https://www.ncbi.nlm.nih.gov/pubmed/37073797
http://dx.doi.org/10.1177/17534666231167353
_version_ 1785030291242352640
author Yang, Ting
Cai, Baiqiang
Cao, Bin
Kang, Jian
Wen, Fuqiang
Chen, Yahong
Jian, Wenhua
Wang, Chen
author_facet Yang, Ting
Cai, Baiqiang
Cao, Bin
Kang, Jian
Wen, Fuqiang
Chen, Yahong
Jian, Wenhua
Wang, Chen
author_sort Yang, Ting
collection PubMed
description BACKGROUND: Chronic obstructive pulmonary disease (COPD) management in China is inadequate and there is a need to improve care and outcomes for patients nationwide. OBJECTIVES: The REAL study was designed to generate reliable information on COPD management from a representative sample of Chinese patients with COPD. Here, we present study outcomes related to acute exacerbations. DESIGN: A 52-week, multicentre, prospective, observational study. METHODS: Outpatients (aged ⩾ 40 years) enrolled from 25 tertiary and 25 secondary hospitals across six geographic regions in China were followed for 12 months. Risk factors for COPD exacerbation and disease severity by exacerbation were assessed using multivariate Poisson and ordinal logistic regression models, respectively. RESULTS: Between June 2017 and January 2019, 5013 patients were enrolled, with 4978 included in the analysis. Mean (standard deviation) age was 66.2 (8.9) years. More patients presented with exacerbations in secondary versus tertiary hospitals (59.4% versus 40.2%) and in rural versus urban areas (53.2% versus 46.3%). Overall exacerbation rates differed across regions (range: 0.27–0.84). Patients from secondary versus tertiary hospitals had higher rates of overall exacerbation (0.66 versus 0.47), severe exacerbation (0.44 versus 0.18) and exacerbation that resulted in hospitalisation (0.41 versus 0.16). Across regions and hospital tiers, the rates of overall exacerbation and exacerbations that resulted in hospitalisation were highest in patients with very severe COPD (based on the severity of airflow limitation or GOLD 2017 combined assessment). Strong predictors of exacerbation included demographic and clinical characteristics, modified Medical Research Council scores, mucus purulence, exacerbation history and the use of maintenance mucolytic treatment. CONCLUSION: COPD exacerbation rates varied across regions and were higher in secondary compared with tertiary hospitals in China. Understanding the factors associated with COPD exacerbation may facilitate improved management of COPD exacerbations in China. REGISTRATION: The trial was registered on 20 March 2017 (ClinicalTrials.gov: NCT03131362; https://clinicaltrials.gov/ct2/show/NCT03131362). PLAIN LANGUAGE SUMMARY: Exacerbations in patients with chronic obstructive pulmonary disease in China Background: Chronic obstructive pulmonary disease (COPD) causes progressive and irreversible airflow limitation. As the disease progresses, patients often experience a flare up of symptoms referred to as an exacerbation. There is inadequate management of COPD in China and, therefore, there is a need to improve care and outcomes for patients across the country. Objective: This study aimed to generate reliable information on exacerbations among Chinese patients with COPD to help inform future management strategies. Study design and methods: Patients (aged ⩾ 40 years) were enrolled from 25 secondary and 25 tertiary hospitals across six regions of China. Physicians collected data over 1 year during routine outpatient visits. Results: There were more patients who experienced an exacerbation in secondary versus tertiary hospitals (59% versus 40%) and in rural versus urban areas (53% versus 46%). Patients in different geographic regions experienced varying frequencies of exacerbations over 1 year. Compared with patients from tertiary hospitals, patients from secondary hospitals experienced exacerbations (including exacerbations that were severe and those that resulted in hospitalisation) at a higher frequency over 1 year. Patients with very severe disease experienced exacerbations (including exacerbations that resulted in hospitalisation) at the highest frequency over 1 year, regardless of the patient’s geographic region or hospital tier. Patients who had certain characteristics and symptoms, had exacerbation(s) over the previous year, or received medication that aids in the clearance of mucus were more likely to experience exacerbations. Conclusion: The frequency of exacerbations among Chinese patients with COPD varied between patients living in different geographic regions and between patients presenting to different hospital tiers. Understanding the factors related to the occurrence of an exacerbation may help physicians better manage the disease.
format Online
Article
Text
id pubmed-10126609
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-101266092023-04-26 Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL) Yang, Ting Cai, Baiqiang Cao, Bin Kang, Jian Wen, Fuqiang Chen, Yahong Jian, Wenhua Wang, Chen Ther Adv Respir Dis Original Research BACKGROUND: Chronic obstructive pulmonary disease (COPD) management in China is inadequate and there is a need to improve care and outcomes for patients nationwide. OBJECTIVES: The REAL study was designed to generate reliable information on COPD management from a representative sample of Chinese patients with COPD. Here, we present study outcomes related to acute exacerbations. DESIGN: A 52-week, multicentre, prospective, observational study. METHODS: Outpatients (aged ⩾ 40 years) enrolled from 25 tertiary and 25 secondary hospitals across six geographic regions in China were followed for 12 months. Risk factors for COPD exacerbation and disease severity by exacerbation were assessed using multivariate Poisson and ordinal logistic regression models, respectively. RESULTS: Between June 2017 and January 2019, 5013 patients were enrolled, with 4978 included in the analysis. Mean (standard deviation) age was 66.2 (8.9) years. More patients presented with exacerbations in secondary versus tertiary hospitals (59.4% versus 40.2%) and in rural versus urban areas (53.2% versus 46.3%). Overall exacerbation rates differed across regions (range: 0.27–0.84). Patients from secondary versus tertiary hospitals had higher rates of overall exacerbation (0.66 versus 0.47), severe exacerbation (0.44 versus 0.18) and exacerbation that resulted in hospitalisation (0.41 versus 0.16). Across regions and hospital tiers, the rates of overall exacerbation and exacerbations that resulted in hospitalisation were highest in patients with very severe COPD (based on the severity of airflow limitation or GOLD 2017 combined assessment). Strong predictors of exacerbation included demographic and clinical characteristics, modified Medical Research Council scores, mucus purulence, exacerbation history and the use of maintenance mucolytic treatment. CONCLUSION: COPD exacerbation rates varied across regions and were higher in secondary compared with tertiary hospitals in China. Understanding the factors associated with COPD exacerbation may facilitate improved management of COPD exacerbations in China. REGISTRATION: The trial was registered on 20 March 2017 (ClinicalTrials.gov: NCT03131362; https://clinicaltrials.gov/ct2/show/NCT03131362). PLAIN LANGUAGE SUMMARY: Exacerbations in patients with chronic obstructive pulmonary disease in China Background: Chronic obstructive pulmonary disease (COPD) causes progressive and irreversible airflow limitation. As the disease progresses, patients often experience a flare up of symptoms referred to as an exacerbation. There is inadequate management of COPD in China and, therefore, there is a need to improve care and outcomes for patients across the country. Objective: This study aimed to generate reliable information on exacerbations among Chinese patients with COPD to help inform future management strategies. Study design and methods: Patients (aged ⩾ 40 years) were enrolled from 25 secondary and 25 tertiary hospitals across six regions of China. Physicians collected data over 1 year during routine outpatient visits. Results: There were more patients who experienced an exacerbation in secondary versus tertiary hospitals (59% versus 40%) and in rural versus urban areas (53% versus 46%). Patients in different geographic regions experienced varying frequencies of exacerbations over 1 year. Compared with patients from tertiary hospitals, patients from secondary hospitals experienced exacerbations (including exacerbations that were severe and those that resulted in hospitalisation) at a higher frequency over 1 year. Patients with very severe disease experienced exacerbations (including exacerbations that resulted in hospitalisation) at the highest frequency over 1 year, regardless of the patient’s geographic region or hospital tier. Patients who had certain characteristics and symptoms, had exacerbation(s) over the previous year, or received medication that aids in the clearance of mucus were more likely to experience exacerbations. Conclusion: The frequency of exacerbations among Chinese patients with COPD varied between patients living in different geographic regions and between patients presenting to different hospital tiers. Understanding the factors related to the occurrence of an exacerbation may help physicians better manage the disease. SAGE Publications 2023-04-19 /pmc/articles/PMC10126609/ /pubmed/37073797 http://dx.doi.org/10.1177/17534666231167353 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Yang, Ting
Cai, Baiqiang
Cao, Bin
Kang, Jian
Wen, Fuqiang
Chen, Yahong
Jian, Wenhua
Wang, Chen
Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)
title Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)
title_full Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)
title_fullStr Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)
title_full_unstemmed Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)
title_short Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)
title_sort exacerbation in patients with stable copd in china: analysis of a prospective, 52-week, nationwide, observational cohort study (real)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126609/
https://www.ncbi.nlm.nih.gov/pubmed/37073797
http://dx.doi.org/10.1177/17534666231167353
work_keys_str_mv AT yangting exacerbationinpatientswithstablecopdinchinaanalysisofaprospective52weeknationwideobservationalcohortstudyreal
AT caibaiqiang exacerbationinpatientswithstablecopdinchinaanalysisofaprospective52weeknationwideobservationalcohortstudyreal
AT caobin exacerbationinpatientswithstablecopdinchinaanalysisofaprospective52weeknationwideobservationalcohortstudyreal
AT kangjian exacerbationinpatientswithstablecopdinchinaanalysisofaprospective52weeknationwideobservationalcohortstudyreal
AT wenfuqiang exacerbationinpatientswithstablecopdinchinaanalysisofaprospective52weeknationwideobservationalcohortstudyreal
AT chenyahong exacerbationinpatientswithstablecopdinchinaanalysisofaprospective52weeknationwideobservationalcohortstudyreal
AT jianwenhua exacerbationinpatientswithstablecopdinchinaanalysisofaprospective52weeknationwideobservationalcohortstudyreal
AT wangchen exacerbationinpatientswithstablecopdinchinaanalysisofaprospective52weeknationwideobservationalcohortstudyreal